Physician profile
Osei Whyte
NPI 1669727624
$2,737.44
in general payments reported to CMS, 2019-2025
26 companies · $550 in 2025
The $550 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $455 · 2021: $557 · 2022: $270 · 2023: $334 · 2024: $464 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,348.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $676.32 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $449.69 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $239.78 | 2019-2022 | |
| Astellas Pharma US INC | $211.42 | 2020-2025 | Veozah |
| Abbvie INC. | $181.70 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $140.68 | 2019-2025 | |
| Dexcom, INC. | $101.26 | 2021-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $90.35 | 2019-2024 | Airsupra, Farxiga |
| Abbott Laboratories | $79.67 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $76.08 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.01 | 2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.84 | 2021-2024 | Ofev |
| Biohaven Pharmaceutical Holding Company LTD. | $45.23 | 2022 | |
| Glaxosmithkline, LLC. | $37.00 | 2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $36.30 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.21 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.71 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $33.21 | 2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $24.04 | 2025 | Inspire |
| Ucb, INC. | $21.87 | 2024 | Rystiggo |
| Biogen, INC. | $18.55 | 2025 | Leqembi |
| Upsher-Smith Laboratories LLC | $17.88 | 2022 | |
| Insulet Corporation | $17.11 | 2024 | Omnipod |
| Esperion Therapeutics, INC. | $16.27 | 2024 | Nexletol |
| Exact Sciences Corporation | $15.57 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osei Whyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.